

5th ACSS at UCSF Biomedicine and Biotechnology Symposium

When: 10am-4pm, Saturday, Dec 8th, 2007

Location: Genentech Hall, 600 16th St., San Francisco, CA 94107

Agenda:

10:00-10:20 Registration and networking

10:20-10:30 Welcome and Opening Comments

10:30-11:00 Dr. Weihai Ying

Some Thoughts about Creative Thinking, Paper Writing, and Grant Writing

11:00-11:30 Dr. Guoliang Yu

Development of Biomarkers for Stem Cells and Cancer Cells Using Rabbit Monoclonal antibodies

11:30-12:00 Dr. Longcheng Li

Small RNA mediated gene regulation in cancer

12:00-12:30 Dr. Jianlong Lou

Botulinum Neurotoxins: Double Faced Friends or Foes?

12:30-1:20 Lunch break

1:20-1:50 Dr. Xiaozhu Huang

Loss of SLC38a2 results in lung development defect and growth retardation.

1:50-2:20 Dr. Chao Tang

Computational Systems Biology

2:20-2:50 Dr. Hua Su

Gene and Cell therapies for myocardial infarction

2:50-3:00 Break

3:00-3:30 Dr. Frank Fanqing Chen

Application of Nanotechnology in Biomedicine

3:30-4:00 Dr. Baoxue Yang

Some suggestions on getting collaborations and position in China

For registration: www.ucbbs.org, then go “announcement”

Organizations: Association of Chinese Students and Scholars (ACSS) at UCSF
Chinese American BioPharmaceuticals Society (CABS, SAPA-WEST)

Sponsorship: Invitrogen, Wisbiomed; Associates of Cape Cod, InC; Epitomics

Liaison: Xiaodong Zhu (xiaodong.zhu@ucsf.edu)

Audience: Staff, Faculty, Postdocs and Students

Free lunch will be served

Speakers Biographies

Weihai Ying, Assistant Adjunct Professor of UCSF

Dr. Weihai Ying got B.S. degree from Shanghai Medical University. After getting Ph.D. of Biochemistry and Molecular Biology in US, Dr. Ying became a postdoc at UCSF Dept. of Neurology, and then became an Assistant Adjunct Professor of UCSF Dept. of Neurology at 2003. He has been the PI of multiple research grants from NIH, VA, Department of Defense and American Heart Association. He has also been a regular member of the Brain Study section of American Heart Association. Dr. Ying has acted as Managing Editor or Editor of biomedical research journals/books. He has achieved international recognition in the research field about novel biological properties of NAD⁺ and NADH and mechanisms of oxidative neural cell death: In 2007 alone he has had four invited reviews and two invited Editorials published or in press, some of which are published in the leading journals in the field. Dr. Ying has also been invited speakers, Session Chairs or organizers in multiple international biomedical research conferences. Dr. Ying has given a number of invited speeches in Chinese Academy of Science and multiple top Chinese universities, and has close cooperation with multiple leading researchers and administrators in top Chinese research institutions.

Guoliang Yu, CEO of Epitomics

Dr. Guoliang Yu is a biotechnologist and entrepreneur with more than 12 years of experience in genomics, and 24 years of experience in life sciences research. Before co-founding Epitomics, Dr. Yu was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. At Mendel Biotechnology, Dr. Yu established a robust functional genomics program, exceeded all six milestones for the Research Agreement with Monsanto and Savia, and managed over 60 Ph.D. scientists and research associates. Before joining Mendel Biotechnology, Dr. Yu was with Human Genome Sciences, Inc., a prominent genomics company, as one of the first Senior Scientists involved in the establishment of the high throughput gene discovery program. While at Human Genome Sciences, Dr. Yu led the technology development group and cancer group. He identified and characterized numerous genes for therapeutic protein and drug discovery. Dr. Yu was a Post-doctoral Fellow at the Harvard Medical School. He holds a Ph.D.

degree in Molecular Biology from the University of California, Berkeley and a B.S. degree in Biochemistry from Fudan University, Shanghai, China. Dr. Yu is also the founder of the Chinese Biopharmaceutical Association headquartered in Washington DC. He is co-inventor and co-author of over 100 patents and scientific articles.

Long-Cheng Li, Assistant Professor, UCSF

Long-Cheng Li is currently an Assistant Professor at the Department of Urology, UCSF. He obtained his medical degrees in Tongji Medical University, China. He came to the US in 1998 and worked in the Urology Research Laboratory in the VA Medical Center San Francisco as a visiting scholar. He was employed in 2000 by DoubleTwist, Inc. Oakland as a Bioinformatics Scientist. Since 2001, He worked at VA Medical Center San Francisco as a Research Scientist and Assistant Researcher. His main research interests have been cancer epigenetics and small RNA mediated gene regulation. He was the first to identify the small RNA-mediated gene activation mechanism or RNAa. In 1999, he created the popular bioscience website Protocol Online. He also developed several gene related databases and bioinformatics tools. His current research focuses on microRNA mediated gene regulation in cancer.

Jianlong Lou, Assistant Researcher, UCSF

Dr. Jianlong Lou is now the group leader and assistant researcher for multi-million dollar BoNT related research projects at Marks Lab, UCSF. All BoNT projects are supported by NIH, DoD, CDC, and industry partners and headed by professor James D Marks. Dr. Jianlong Lou got his MD and Ph.D from Chinese Academy of Preventive Medicine and Peking University in 1993. His systematic research work on Sterigmatocystin was awarded three times by three department of Chinese Central Government in 1993, 1994 and 1995. And he was the sole author for two book chapters on Sterigmatocystin and co-author for over 25 peer-reviewed research papers. Dr. Lou was the co-inventor of two US and Global patents. Dr. Lou was the deputy director of monoclonal antibody lab at life sciences center at Peking University from 1994-1997. Dr. Lou had his first post-doc training in the protein engineering national lab at Peking University and his second post-doc training in phage display technology with Dr. Andrew Bradbury at SISS/ICGEB in Italy. He joined Marks' lab in 2000 as a specialist. Besides the traditional hybridoma and phage display technology, Dr. Lou also

adapted and improved the yeast display system and mammalian cell human antibody production system for the BoNT research and other projects, he also created several new vectors for antibody display at Marks lab. All the training and experience made him a real expert in antibody engineering.

Xiaozhu Huang, Associate Professor, UCSF

Dr. Xiaozhu Huang received her medical degree from the Tongji Medical University in Wuhan, China. She came to UCSF in 1992 as a post-doctoral fellow and joined the faculty of the school of medicine in 1999. Currently, she is the director of the animal physiology and morphology core facility, UCSF Sandler Center for Basic Research in Asthma. Her major academic interests are in the areas of biological functions of integrins and genetic contributions of pulmonary diseases including asthma.

Chao Tang, Professor, UCSF

Dr. Chao Tang went to the University of Science and Technology of China as an undergraduate. He came to US for graduate study and received a PhD in physics at the University of Chicago. He spent many years in the NEC Research Institute in Princeton where he got interested in biological problems. He joined UCSF about two and a half years ago, as a professor in the departments of Biopharmaceutical Sciences and of Biochemistry and Biophysics. He is also a QB3 affiliate where he office and lab reside. His research interest is at the interface between physical and biological sciences. He is a member of the UCSF Systems Biology Leadership Group. Dr. Tang has a very close tie with the scientific community in China. He is the director of the Center for Theoretical Biology at Peking University and also a Chang Jiang Guest (Jiang Zuo) Professor there.

Hua Su, Assistant Professor, UCSF

Hua Su is an Assistant Professor in the Department of Medicine at University of California, San Francisco. Her research is focus on (1) adeno-associated viral vector (AAV) mediated gene transfer; (2) angiogenesis; (3) gene therapy for cardiovascular disease; and (4) adult and embryonic stem cells mediated myocardial regeneration. She has developed an AAV vector that can mediate targeted gene expression in ischemic myocardium. She has published numerical research papers in peer-reviewed journals, including PNAS.

Fanqing Frank Chen, Scientist at Lawrence Berkeley National Laboratory

Dr. Fanqing Frank Chen is a scientist at Lawrence Berkeley National Laboratory at the University of California. Frank is on the Editorial Board of Nanotoxicology, the first journal fully dedicated to nanotoxicity. His main interest is in nano-bio hybrid structure for biosensors, clinical imaging, and nano-bio interaction. He is also the first one to use quantitative biology approach to decipher the health impact of nanomaterials at the molecular level. His study on nanotoxicity was highlighted in the Washington Post. He is also organizer of the Chinese Nanosafety Committee, and on organizing committee of Nanotoxicology conference (U.S. and Europe). Dr. Chen is one of the founding members of the Berkeley Nano Roundtable. Dr. Chen got his B.S. degree in 1991 from Fudan University in Shanghai, China, and his Ph.D. from joint graduate program of Los Alamos National Laboratory and the University of New Mexico in 1997. He did postdoc research in Los Alamos and NYU Mount Sinai Hospital. He joined Lawrence Berkeley National Laboratory in 2000 and has worked there since then. He is also adjunct professor in Fudan University, Zhejiang University in China, and founder for a new nanomedicine institute in Jiangsu, China

Baoxue Yang, Assistant Professor, UCSF

Dr. Baoxue Yang is an assistant professor at Department of Medicine, UCSF. His research field is physiology of membrane transporters. Funding from NIH, American Heart Association and PKD Foundation has supported his research work. Yang got his Ph. D. degree in 1993 from Bethune University of Medical Sciences, Changchun, China. He did postdoc research in CVRI, UCSF. He has been working in Department of Medicine, UCSF since 1997. Recently he has got an offer of professor position at Peking University in China and he will take this position soon. He is also a visiting professor in Jilin University and Northeast Normal University in China.